Oscotec applies for U.S. clinical 2a IND of its rheumatoid arthritis treatment

Oscotec(CEo Jung-Geun Kim), a new drug developing company, announced on the 26^th that the company applied for a IND for a clinical 2a study to the U.S. FDA as completing Phase I SAD(single ascending dose) & MAD(multiple ascending dose) studies of ‘SKI-O-703,’ a new drug candidate which selectively inhibits SYK kinase proteins, a target of various inflammatory treatments, such as rheumatoid arth...